More Neurizon Therapeutics Limited news
Neurizon Therapeutics LimitedASX: NUZ

Preliminary Positive Results for the Treatment of SARS-CoV-2

Jun 3, 2020 at 11:41 PM EDT · Issued by Neurizon Therapeutics Limited

Filed with ASX · Jun 3, 2020 at 11:41 PM EDT

On 6ix: 6ix.com/news/preliminary-positive-results-for-the-treatment-of-sars-cov-2

Neurizon Therapeutics Limited has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Neurizon Therapeutics Limited on 6ix

Earlier from Neurizon Therapeutics

  • Suspension from Official QuotationJun 2, 2020
  • Monepantel Trial Achieves Successful Anti-Cancer OutcomeMay 11, 2020
  • PharmAust to Evaluate Monepantel on COVID-19Apr 16, 2020
  • Brisbane Animal Hospital Joins Phase II Dog Cancer TrialMar 2, 2020
  • PharmAust Receives $700k R&D Tax Incentive RefundJan 14, 2020

Later from Neurizon Therapeutics

  • Virtual Investor Briefing PresentationJun 9, 2020
  • Voluntary SuspensionJun 14, 2020
  • Confirmation of Preliminary COVID-19 ResultsJun 17, 2020
  • Reinstatement to Official QuotationJun 17, 2020
  • Inhibition of SARS-CoV-2 by MPL in Human Respiratory CellsAug 24, 2020
All Neurizon Therapeutics news releases↗

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer